Carbohydrate-Based Antiviral Vaccines

Carbohydrate-Based Vaccines and Immunotherapies

Volumn , Issue , 2008, Pages 167-193

  Swarts, Benjamin M ^a   Guo, Zhongwu ^a  

^a WAYNE STATE UNIVERSITY   (United States)

Author keywords

Carbohydrate based antiviral vaccines; Host cell mediated N glycosylation of viral envelope proteins; Vaccine and drug development

Indexed keywords

EID: 84870416955     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470473283.ch5     Document Type: Chapter

References (154)

1. Patterson K, Runge T (2002) Smallpox and the Native American. Am. J. Med. Sci. 323:216-222.
2. Johnson NPAS, Mueller J (2002) Updating the accounts: Global mortality of the 1918-1920 "Spanish" influenza pandemic. B. Hist. Med. 76:105-115.
3. UNAIDS (2007) Overview of the global aids epidemic. Available at: http://www.unaids.org/en/KnowledgeCentre/HIVData/.
4. Idilman R, Maria ND, Colantoni A, Thiel DHV (1998) Pathogenesis of hepatitis B and C-induced hepatocellular carcinoma. J. Viral Hepat. 5:285-299.
5. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S (2007) Human papillomavirus and cervical cancer. Lancet 370:890-907.
6. Vigerust DJ, Shepherd VL (2007) Virus glycosylation: Role in virulence and immune interactions. Trends Microbiol. 15:211-218.
7. Weerapana E, Imperiali B (2006) Asparagine-linked protein glycosylation: From eukaryotic to prokaryotic systems. Glycobiology 16:91R-101R.
8. Varki A (1993) Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:97-130 and references cited therein.
9. Lehle L, Strahl S, Tanner W (2006) Protein glycosylation, conserved from yeast to man: A model organism helps elucidate congenital human diseases. Angew. Chem. Int. Ed. Engl. 45:6801-6818.
10. Helenius A, Aebi M (2004) Roles of N-linked glycans in the endoplasmic reticulum. Annu. Rev. Biochem. 73:1019-1049.
11. Wyatt R, Sodroski J (1998) The HIV-1 envelope glycoproteins: Fusogens, antigens, and immunogens. Science 280:1884-1888.
12. Center RJ, Leapman RD, Lebowitz J, Arthur LO, Earl PL, Moss B (2002) Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J. Virol. 76:7863-7867.
13. Chan DC, Fass D, Berger JM, Kim PS (1997) Core structure of gp41 from the HIV envelope glycoprotein. Cell 89:263-273.
14. McDougal JS, Kennedy MS, Sligh JM, Cort SP, Mawle A, Nicholson JK (1986) Binding of HTLV-III/LAV to T4+ T cells by a complex of the 110K viral protein and the T4 molecule. Science 231:382-385.
15. Myers G, MacInnes K, Korber B (1992) The emergence of simian/human immunodeficiency viruses. AIDS Res. Hum. Retroviruses 8:373-386.
16. Geyer H, Holschbach C, Hunsmann G, Schneider J (1988) Carbohydrates of human immunodeficiency viru. Structures of oligosaccharides linked to the envelope glycoprotein 120. J. Biol. Chem. 263:11760-11767.
17. Veronese FD, DeVico AL (1985) Characterization of gp41 as the transmembrane protein coded by the HTLV-III/LAV envelope gene. Science 229:1402-1405.
18. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG (1998) The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 393:705-711.
19. Cutalo JM, Deterding LJ, Tomer KB (2004) Characterization of glycopeptides from HIVISF2 gp120 by liquid chromatography mass spectrometry. J. Am. Chem. Mass Spectrom. 15:1545-1555.
20. Zhu X, Borchers C, Bienstock RJ, Tomer KB (2000) Mass spectrometric characterization of the glycosylation pattern of HIV-gp120 expressed in CHO cells. Biochemistry 39:11194-11204.
21. Leonard CK, Spellman MW, Riddle L, Harris RJ, Thomas JN, Gregory TJ (1990) Assignment of intrachain disulfide bonds and characterization of potential glycosylation sites of the type 1 recombinant human immunodeficiency virus envelope glycoprotein (gp120) expressed in Chinese hamster ovary cells. J. Biol. Chem. 265:10373-10382.
22. Zhang M, Gaschen B, BlayW, FoleyB, Haigwood N, Kuiken C, KorberB (2004) Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology 14:1229-1246.
23. Wei X, Decker JM,Wang S, Hui H, Kappes JC, Wu X, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM (2004) Antibody neutralization and escape by HIV-1. Nature 422:307-312.
24. Scanlan CN, Offer J, Zitzmann N, Dwek RA (2007) Exploiting the defensive sugars of HIV-1 for drug and vaccine design. Nature 446:1038-1045.
25. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA (2003) Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 300:2065-2071.
26. Woods RJ, Pathiaseril A, Wormald MR, Edge CJ, Dwek RA (1998) The high degree of internal flexibility observed for an oligomannose oligosaccharide does not alter the overall topology of the molecule. Eur. J. Biochem. 258:372-386.
27. Chen B, Vogan EM, Gong H, Skehel JJ,Wiley DC, Harrison SC (2005) Determining the structure of an unliganded and fully glycosylated SIV gp120 envelope glycoprotein. Structure 13:197-211.
28. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433:834-841.
29. Dash B, McIntosh A, Barrett W, Daniels R (1994) Deletion of a single N-linked glycosylation site from the transmembrane envelope protein of human immunodeficiency virus type 1 stops cleavage and transport of gp160 preventing env-mediated fusion. J. Gen. Virol. 75:1389-1397.
30. Fenouillet E, Jones IM (1995) The glycosylation of human immunodeficiency virus type 1 transmembrane glycoprotein (gp41) is important for the efficient intracellular transport of the envelope precursor gp160. J. Gen. Virol. 76:1509-1514.
31. Li Y, Luo L, Rasool N, Kang CY (1993) Glycosylation is necessary for the correct folding of human immunodeficiency virus gp120 in CD4 binding. J. Virol. 67:584-588.
32. Montefiori DC, Robinson WE, Mitchell WM (1988) Role of protein N-glycosylation in pathogenesis of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U. S. A. 85:9248-9252.
33. Fenouillet E, Gluckman JC, Bahraoui E (1990) Role of N-linked glycans of envelope glycoproteins in infectivity of human immunodeficiency virus type 1. J. Virol. 64:2841-2848.
34. Gruters RA, Neefjes JJ, Tersmette M, de Goede REY, Tulp A, Huisman HG, Miedema F, Ploegh HL (1987) Interference with HIV-induced syncytium formation and viral infectivity by inhibitors of trimming glucosidase. Nature 330:74-77.
35. Pal R, Hoke GM, Sarngadharan MG (1989) Role of oligosaccharides in the processing and maturation of envelope glycoproteins of human immunodeficiency virus type 1. Proc. Natl. Acad. Sci. U.S.A. 86:3384-3388.
36. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nature Med. 4:679-684.
37. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V (2001) Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58:19-42.
38. Sagar M, Wu X, Lee S, Overbaugh J (2006) Human immunodeficiency virus type 1 V1-V2 envelope loop sequences expand and add glycosylation sites over the course of infection, and these modifications affect antibody neutralization sensitivity. J. Virol. 80:9586-9598.
39. Wolk T, Schreiber M (2006) N-glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med. Microbiol. Immunol. (Berl.) 195:165-172.
40. Wagner R, Matrosovich M, Klenk H (2002) Functional balance between haemagglutinin and neuraminidase in influenza virus infections. Rev. Med. Virol. 12:159-166.
41. Klenk H-D, Wagner R, Heuer D, Wolff T (2002) Importance of hemagglutinin glycosylation for the biological functions of influenza virus. Virus Res. 82:73-75.
42. Daniels R, Kurowski B, Hebert AEJN (2003) N-linked glycans direct the cotranslational folding pathway of influenza hemagglutinin. Mol. Cell 11:79-90.
43. Wagner R,Wolff T, Herwig A, Pleschka S, Klenk H-D (2000) Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: A study by reverse genetics. J. Virol. 74:6316-6323.
44. Baignet SJ, McCauley JW (2001) Glycosylation of haemagglutinin and stalk-length of neuraminidase combine to regulate the growth of avian influenza viruses in tissue culture. Virus Res. 79:177-185.
45. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Nakamura K (2002) Role of overlapping glycosylation sequons in antigenic properties, intracellular transport and biological activities of influenza A/H2N2 virus haemagglutinin. J. Gen. Virol. 83:3067-3074.
46. Tsuchiya E, Sugawara K, Hongo S, Matsuzaki Y, Muraki Y, Li Z-N, Nakamura K (2002) Effect of addition of new oligosaccharide chains to the globular head of influenza A/H2N2 virus haemagglutinin on the intracellular transport and biological activities of the molecule. J. Gen. Virol. 83:1137-1146.
47. Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Hongo YM (2004) Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza A/H3N2 virus hemagglutinin. J. Virol. 78:9605-9611.
48. Kaverin NV, Rudneva IA, Ilyushina NA, Varich NL, Lipatov AS, Smirnov YA, Govorkova EA, Gitelman AK, Lvov DK, Webster RG (2002) Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants. J. Gen. Virol. 83:2497-2505.
49. Segawa H, Inakawa A, Yamashita T, Taira H (2003) Functional analysis of individual oligosaccharide chains of Sendai virus hemagglutinin-neuraminidase protein. Biosci. Biotechnol. Biochem. 67:592-598.
50. Skehel JJ, Stevens DJ, Daniels RS, Douglas AR, Knossow M, Wilson IA, Wiley DC (1984) A carbohydrate side chain on hemagglutinins of Hong Kong influenza viruses inhibits recognition by a monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 81:1779-1783.
51. Wilson IA, Wiley JJSC (1981) Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3A° resolution. Nature 289:366-373.
52. Basak S, Pritchard DG, Bhown AS, Compans RW (1981) Glycosylation sites of influenza viral glycoproteins: Characterization of tryptic glycopeptides from the A/USSR(H1N1) hemagglutinin glycoprotein. J. Virol. 37:549-558.
53. Ward CW, Dopheide TA (1981) Amino acid sequence and oligosaccharide distribution of the haemagglutinin from an early Hong Kong influenza virus variant A/Aichi/2/68 (X-31). Biochem. J. 193:953-962.
54. Mir-Shekari SY, Ashford DA, Harvey DJ, Dwek RA, Schulze IT (1997) The glycosylation of the influenza A virus hemagglutinin by mammalian cells. A site-specific study. J. Biol. Chem. 272:4027-4036.
55. Gallagher PJ, Henneberry JM, Sambrook JF, Gething MJ (1992) Glycosylation requirements for intracellular transport and function of the hemagglutinin of influenza virus. J. Virol. 66:7136-7145.
56. Roberts PC, Garten W, Klenk HD (1993) Role of conserved glycosylation sites in maturation and transport of influenza A virus hemagglutinin. J. Virol. 67:3048-3060.
57. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K (1991) Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagglutinins of influenza A viruses. Virology 182:475-485.
58. Igarashi M, Ito K, Kida H, Takada A (2008) Genetically destined potentials for N-linked glycosylation of influenza virus hemagglutinin. Virology 376:323-329.
59. Vigerust D, Ulett K, Boyd K, Madsen J, Hawgood S, McCullers J (2007) N-linked glycosylation attenuates H3N2 influenza viruses. J. Virol. 81:8593-8600.
60. Gallagher P, Henneberry J, Wilson I, Sambrook J, Gething M (1988) Addition of carbohydrate side chains at novel sites on influenza virus hemagglutinin can modulate the folding, transport, and activity of the molecule. J. Cell Biol. 107:2059-2073.
61. Deshpande KL, Fried VA, Ando M,Webster RG (1987) Glycosylation affects cleavage of an H5N2 influenza virus hemagglutinin and regulates virulence. PNAS 84:36-40.
62. Ohuchi M, Ohuchi R, Feldmann A, Klenk H (1997) Regulation of receptor binding affinity of influenza virus hemagglutinin by its carbohydrate moiety. J. Virol. 71:8377-8384.
63. Wagner R, Heuer D, Wolff T, Herwig A, Klenk H-D (2002) N-glycans attached to the stem domain of haemagglutinin efficiently regulate influenza A virus replication. J. Gen. Virol. 83:601-609.
64. Ohuchi R, Ohuchi M, Garten W, Klenk H (1997) Oligosaccharides in the stem region maintain the influenza virus hemagglutinin in the metastable form required for fusion activity. J. Virol. 71:3719-3725.
65. Op De Beeck A, Cocquerel L, Dubuisson J (2001) Biogenesis of hepatitis C virus envelope glycoproteins. J. Gen. Virol. 82:2589-2595.
66. Goffard A (2003) Glycosylation of hepatits C virus envelope proteins. Biochemie 85:295-301.
67. Helle F, Goffard A, Morel V, Duverlie G, McKeating J, Keck Z-Y, Foung S, Penin F, Dubuisson J, Voisset C (2007) The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 81:8101-8111.
68. Meunier J-C, Fournillier A, Choukhi A, Cahour A, Cocquerel L, Dubuisson J, Wychowski C (1999) Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex. J. Gen. Virol. 80:887-896.
69. Nakano I, Fukuda Y, Katano Y, Hayakawa T (1998) Conformational epitopes detected by cross-reactive antibodies to envelope 2 glycoprotein of the hepatitis C virus. J. Infect. Dis. 180:1328-1333.
70. Slater-Handshy T, Droll DA, Fan X, Bisceglie AMD, Chambers TJ (2004) HCV E2 glycoprotein: Mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing. Virology 319:36-48.
71. Goffard A, Callens N, Bartosch B, Wychowski C, Cosset F-L, Montpellier C, Dubuisson J (2005) Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79:8400-8409.
72. Li P, Wan Q, Feng Y, Liu M, Wu J, Chen X, Zhang X-L (2006) Engineering of Nglycosylation of hepatitis C virus envelope protein E2 enhances T cell responses for DNA immunization. Vaccine 25:1544-1551.
73. Liu M, Chen H, Luo F, Li P, Pan Q, Xia B, Qi Z, Ho W-Z, Zhang X-L (2007) Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine 25:6572-6580.
74. Lozach P-Y, Lortat-Jacob H, de Lavalette DA, Staropoli I, Foung S, Amara A, Houles C, Fieschi F, Schwartz O, Virelizier J-L, Arenzana-Seisdedos F, Altmeyer R (2003) DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278:20358-20366.
75. Wang Q, Feng Z, Nie Q, Zhou Y (2004) DC-SIGN: Binding receptors for hepatitis C virus. Chin. Med. J. 117:1395-1400.
76. Cormier EG, Durso RJ, TsamisF, Boussemart L,Manix C, OlsonWC,Gardner JP,DragicT (2004) L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 101:14067-14072.
77. Lozach P-Y, Amara A, Bartosch B, Virelizier J-L, Arenzana-Seisdedos F, Cosset F-L, Altmeyer R (2004) C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J. Biol. Chem. 279:32035-32045.
78. Iacob RE, Perdivara I, Przybylski M, Tomer KB (2008) Mass spectrometric characterization of glycosylation of hepatitis C virus E2 envelope glycoprotein reveals extended microheterogeneity of N-glycans. J. Am. Soc. Mass Spectrom. 19:428-444.
79. Bertaux C, Daelemans D, Meertens L, Cormier EG, Reinus JF, Peumans WJ, Van Damme EJM, Igarashi Y, Oki T, Schols D, Dragic T, Balzarini J (2007) Entry of hepatitis C virus and human immunodeficiency virus is selectively inhibited by carbohydrate-binding agents but not by polyanions. Virology 366:40-50.
80. Helle F, Wychowski C, Vu-Dac N, Gustafson KR, Voisset C, Dubuisson J (2006) Cyanovirin-N inhibits hepatitis C virus entry by binding to envelope protein glycans. J. Biol. Chem. 281:25177-25183.
81. Wang T, Anderson J, Magnarelli L, Bushmich S,Wong S, Koski R, Fikrig E (2001)West Nile virus envelope protein: Role in diagnosis and immunity. Ann. N. Y. Acad. Sci. 951:325-327.
82. Chambers TJ, Hahn CS, Galler R, Rice CM (1990) Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
83. Shirato K, Miyoshi H, Goto A, Ako Y, Ueki T, Kariwa H, Takashima I (2004) Viral envelope protein glycosylation is a molecular determinant of the neuroinvasiveness of the New York strain of West Nile virus. J. Gen. Virol. 85:3637-3645.
84. Beasley DWC, Whiteman MC, Zhang S, Huang CY-H, Schneider BS, Smith DR, Gromowski GD, Higgs S, Kinney RM, Barrett ADT (2005) Envelope protein glycosylation status influences mouse neuroinvasion phenotype of genetic lineage 1West Nile virus strains. J. Virol. 79:8339-8347.
85. Halevy M, Akov Y, Ben-Nathan D, Kobiler D, Lachmi B, Lustig S (1994) Loss of active neuroinvasiveness in attenuated strains ofWest Nile virus: Pathogenicity in immunocompetent and SCID mice. Arch. Virol. 137:355-370.
86. Lad V, Shende V, Gupta A, Koshy A, Roy A (2000) Effect of tunicamycin on expression of epitopes on Japanese encephalitis virus glycoprotein E in porcine kidney cells. Acta Virol. 44:359-364.
87. Hanna SL, Pierson TC, Sanchez MD, Ahmed AA, Murtadha MM, Doms RW (2005) N-linked glycosylation of West Nile virus envelope proteins influences particle assembly and infectivity. J. Virol. 79:13262-13274.
88. Li J, Bhuvanakantham R, Howe J, Ng M-L (2006) The glycosylation site in the envelope protein ofWest Nile virus (Sarafend) plays an important role in replication and maturation processes. J. Gen. Virol. 87:613-622.
89. DavisCW,Mattei LM, Nguyen H-Y, Ansarah-Sobrinho C, DomsRW, Pierson TC (2006) The location of asparagine-linked glycans on West Nile virions controls their Interactions with CD209 (dendritic cell-specific ICAM-3 grabbing nonintegrin). J. Biol. Chem. 281:37183-37194.
90. Davis CW, Nguyen H-Y, Hanna SL, Sánchez MD, Doms RW, Pierson TC (2006) West Nile virus discriminates between DC-SIGN and DC-SIGNR for cellular attachment and infection. J. Virol. 80:1290-1301.
91. Sanchez A, Yang Z-Y, Xu L, Nabel GJ, Crews T, Peters CJ (1998) Biochemical analysis of the secreted and virion glycoproteins of ebola virus. J. Virol. 72:6442-6447.
92. Feldmann H, Nichol ST, Klenk H-D, Peters CJ, Sanchez A (1994) Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. Virology 199:469-473.
93. Dowling W, Thompson E, Badger C, Mellquist J, Garrison A, Smith J, Paragas J, Hogan R, Schmaljohn C (2007) Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines. J. Virol. 81:1821-1837.
94. Lin G, Simmons G, Pöhlmann S, Baribaud F, Ni H, Leslie GJ, Haggarty BS, Bates P, Weissman D, Hoxie JA, Doms RW (2003) Differential N-linked glycosylation of human immunodeficiency virus and ebola virus envelope glycoproteins modulates interactions with DC-SIGN and DC-SIGNR. J. Virol. 77:1337-1346.
95. Barrientos L, Gronenborn A (2005) The highly specific carbohydrate-binding protein cyanovirin-N: Structure, anti-HIV/Ebola activity and possibilities for therapy. Mini. Rev. Med. Chem. 5:21-31.
96. Barrientos LG, O'Keefe BR, Bray M, Sanchez A, Gronenborn AM, Boyd MR (2003) Cyanovirin-N binds to the viral surface glycoprotein, GP1,2 and inhibits infectivity of Ebola virus. Antiviral Res. 58:47-56.
97. Rota P, Oberste M, Monroe S, NixW, Campagnoli R, Icenogle J, Peñaranda S, Bankamp B, Maher K, Chen M, Tong S, Tamin A, Lowe L, Frace M, DeRisi J, Chen Q, Wang D, Erdman D, Peret T, Burns C, Ksiazek T, Rollin P, Sanchez A, Liffick S, Holloway B, Limor J, McCaustland K, Olsen-Rasmussen M, Fouchier R, Günther S, Osterhaus A, Drosten C, Pallansch M, Anderson L, Bellini W (2003) Characterisation of a novel coronavirus associated with severe acute respiratory syndrome. Science 300:1394-1399.
98. Shih Y, Chen C, Liu S, Chen K, Lee Y, Chao Y, Chen Y (2006) Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus. J. Virol. 80:10315-10324.
99. Han DP, Lohani M, Cho MW (2007) Specific asparagine-linked glycosylation sites are critical for DC-SIGN-and L-SIGN-mediated severe acute respiratory syndrome coronavirus entry. J. Virol. 81:12029-12039.
100. van der Meer FJUM, de Haan CAM, Schuurman NMP, Haijema BJ, Peumans WJ, Van Damme EJM, Delputte PL, Balzarini J, Egberink HF (2007) Antiviral activity of carbohydrate-binding agents against Nidovirales in cell culture. Antiviral Res. 76:21-29.
101. van der Meer FJUM, de Haan CAM, Schuurman NMP, Haijema BJ, Verheije MH, Bosch BJ, Balzarini J, Egberink HF (2007) The carbohydrate-binding plant lectins and the non-peptidic antibiotic pradimicin A target the glycans of the coronavirus envelope glycoproteins. J. Antimicro. Chemother. 60:741-749.
102. Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng Y-R, Patch JR, Choudhary A, Wang L-F, Eaton BT, Broder CC (2005) Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus. J. Virol. 79:6690-6702.
103. Zheng F, Ma L, Shao L,Wang G, Chen F, Zhang Y, Yang S (2007) Defining the N-linked glycosylation site of Hantaan virus envelope glycoproteins essential for cell fusion. J. Microbiol. 45:41-47.
104. Moll M, Kaufmann A, Maisner A (2004) Influence of N-glycans on processing and biological activity of the Nipah virus fusion protein. J. Virol. 78:7274-7278.
105. Schowalter RM, Smith SE, Dutch RE (2006) Characterization of human metapneumovirus F protein-promoted membrane fusion: Critical roles for proteolytic processing and low pH. J. Virol. 80:10931-10941.
106. Griffin C,Wang ECY, McSharry BP, Rickards C, Browne H,Wilkinson GWG, Tomasec P (2005) Characterization of a highly glycosylated form of the human cytomegalovirus HLA class I homologue gpUL18. J. Gen. Virol. 86:2999-3008.
107. Novoa RR, Calderita G, Cabezas P, Elliott RM, Risco C (2005) Key golgi factors for structural and functional maturation of Bunyamwera virus. J. Virol. 79:10852-10863.
108. Melanson VR, Iorio RM (2006) Addition of N-glycans in the stalk of the Newcastle disease virus HN protein blocks. Its interaction with the F protein and prevents fusion. J. Virol. 80:623-633.
109. Kunz S, Rojek JM, Kanagawa M, Spiropoulou CF, Barresi R, Campbell KP, Oldstone MBA (2005) Posttranslational modification of a-dystroglycan, the cellular receptor for arenaviruses, by the glycosyltransferase LARGE is critical for virus binding. J. Virol. 79:14282-14296.
110. Eichler R, Lenz O, GartenW, Strecker T (2006) The role of single N-glycans in proteolytic processing and cell surface transport of the Lassa virus glycoprotein GP.-C. Virology J. 3:41-47.
111. Burton DR, Stanfield RL, Wilson IA (2005) Antibody vs. HIV in a clash of evolutionary titans. Proc. Natl. Acad. Sci. U. S. A. 102:14943-14948.
112. Pantophlet R, Burton DR (2006) Gp120: Target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24:739-769.
113. Conley AJ, Kessler JA, Boots LJ, Tung JS, Arnold BA, Keller PM, Shaw AR, Emini EA (1994) Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody. Proc. Natl. Acad. Sci. U.S.A. 91:3348-3352.
114. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, Moore JP, Stiegler G, Katinger H, Burton DR, Parren PWHI (2001) Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.
115. Burton D, Pyati J, Koduri R, Sharp S, Thornton G, Parren P, Sawyer L, Hendry R, Dunlop N, Nara P, Lamacchia M, Garratty E, Stiehm E, Bryson Y, Cao Y, Moore J, Ho D, Barbas C (1994) Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 266:1024-1027.
116. Trkola A, Pomales A, Yuan H, Korber B, Maddon P, Allaway G, Katinger H, Barbas C, Burton D, Ho D (1995) Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J. Virol. 69:6609-6617.
117. Trkola A, Purtscher M, Muster T, Ballaun C, Buchacher A, Sullivan N, Srinivasan K, Sodroski J, Moore J, Katinger H (1996) Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J. Virol. 70:1100-1108.
118. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, Kwong PD, Moore JP (2002) The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
119. Scanlan CN, Pantophlet R, Wormald MR, Saphire EO, Stanfield R, Wilson IA, Katinger H, Dwek RA, Rudd PM, Burton DR (2002) The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of 12 mannose residues on the outer face of gp120. J. Virol. 76:7306-7321.
120. Calarese DA, Lee H-K, Huang C-Y, Best MD, Astronomo RD, Stanfield RL, Katinger H, Burton DR, Wong C-H, Wilson IA (2005) Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12. Proc. Natl. Acad. Sci. U.S.A. 102:13372-13377.
121. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, Stiegler G, Kunert R, Zolla-Pazner S, Katinger H, Petropoulos CJ, Burton DR (2004) Comprehensive crossclade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
122. Li H, Wang L-X (2004) Design and synthesis of a template-assembled oligomannose cluster as an epitope mimic for human HIV-neutralizing antibody 2G12. Org. Biomol. Chem. 2:483-488.
123. Wang L-X, Ni J, Singh S, Li H (2004) Binding of high-mannose-type oligosaccharides and synthetic oligomannose clusters to human antibody 2G12: Implications for HIV-1 vaccine design. Chem. Biol. 11:127-134.
124. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393:648-659.
125. Lis H, Sharon N (1978) Soybean agglutinin-a plant glycoprotein. Structure of the carboxydrate unit. J. Biol. Chem. 253:3468-3476.
126. Ni J, Song H, Wang Y, Stamatos NM, Wang L-X (2006) Toward a carbohydrate-based HIV-1 vaccine: Synthesis and immunological studies of oligomannose-containing glycoconjugates. Bioconjug. Chem. 17:493-500.
127. Wang J, Li H, Zou G, Wang L-X (2007) Novel template-assembled oligosaccharide clusters as epitope mimics for HIV-neutralizing antibody 2G12. Design, synthesis, and antibody binding study. Org. Biomol. Chem. 5:1529-1540.
128. Lee H-K, Scanlan CN, Huang C-Y, Chang AY, Calarese DA, Dwek RA, Rudd PM, Burton DR, Wilson IA, Wong C-H (2004) Reactivity-based one-pot synthesis of oligomannoses: Defining antigens recognized by 2G12, a broadly neutralizing anti-HIV-1 antibody. Angew. Chem. Int. Ed. Engl. 43:1000-1003.
129. Geng X, Dudkin VY, Mandal M, Danishefsky SJ (2004) In pursuit of carbohydrate-based HIV vaccines, part 2: The total synthesis of high-mannose-type gp120 fragments-evaluation of strategies directed to maximal convergence. Angew. Chem. Int. Ed. Engl. 43:2562-2565.
130. Mandal M, Dudkin VY, Geng X, Danishefsky SJ (2004) In pursuit of carbohydrate-based HIV vaccines, part 1: The total synthesis of hybrid-type gp120 fragments. Angew. Chem. Int. Ed. Engl. 43:2557-2561.
131. Dudkin VY, Orlova M, Geng X, Mandal M, Olson WC, Danishefsky SJ (2004) Toward fully synthetic carbohydrate-based HIV antigen design: On the critical role of bivalency. J. Am. Chem. Soc. 126:9560-9562.
132. Krauss I, Joyce J, Finnefrock A, Song H, Dudkin V, Geng X, Warren J, Chastain M, Shiver J, Danishefsky S (2007) Fully synthetic carbohydrate HIV antigens designed on the logic of the 2G12 antibody. J. Am. Chem. Soc. 129:11042-11044.
133. Zhang ZY, Ollmann IR, Ye X-S,Wischnat R, Baasov T,Wong C-H (1999) Programmable one-pot oligosaccharide synthesis. J. Am. Chem. Soc. 121:734-753.
134. Wang S-K, Liang P-H, Astronomo RD, Hsu T-L, Hsieh S-L, Burton DR, Wong C-H (2008) Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN. Proc. Natl. Acad. Sci. U.S.A. 105:3690-3695.
135. Geijtenbeek TBH, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GCF, Middel J, Cornelissen ILMHA, Nottet HSLM, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y (2000) DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 100:587-597.
136. Luallen RJ, Lin J, Fu H, Cai KK, Agrawal C, Mboudjeka I, Lee F-H, Montefiori D, Smith DF, Doms RW, Geng Y (2008) An engineered saccharomyces cerevisiae strain binds the broadly neutralizing human immunodeficiency virus type 1 antibody 2G12 and elicits mannose-specific gp120-binding antibodies. J. Virol. 82:6447-6457.
137. Ji X, Gewurz H, Spear GT (2005) Mannose binding lectin (MBL) and HIV. Mol. Immunol. 42:145-152.
138. Ezekowitz RA, Kuhlman M, Groopman JE, Byrn RA (1989) A human serum mannosebinding protein inhibits in vitro infection by the human immunodeficiency virus. J. Exp. Med. 169:185-196.
139. Ying H, Ji X, Hart ML, Gupta K, Saifuddin M, Zariffard MR, Spear GT (2004) Interaction of mannose-binding lectin with HIV type 1. Is sufficient for virus opsonization but not neutralization. AIDS Res. Hum. Retroviruses 20:327-335.
140. Hart ML, Saifuddin M, Spear GT (2003) Glycosylation inhibitors and neuraminidase enhance human immunodeficiency virus type 1 binding and neutralization by mannosebinding lectin. J. Gen. Virol. 84:353-360.
141. Geijtenbeek T, van Kooyk Y (2003) DC-SIGN: A novel HIV receptor on DCs that mediates HIV-1 transmission. Curr. Top. Microbiol. Immunol. 276:31-54.
142. Spear GT, Zariffard MR, Xin J, Saifuddin M (2003) Inhibition of DC-SIGN-mediated trans infection of T cells by mannose-binding lectin. Immunology 110:80-85.
143. Balzarini J (2006) Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res. 71:237-247.
144. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D (2007) Carbohydratebinding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol. Pharmacol. 71:3-11.
145. Esser MT, Mori T, Mondor I, Sattentau QJ, Dey B, Berger EA, Boyd MR, Lifson JD (1999) Cyanovirin-N binds to gp120 to interfere with CD4-dependent human immunodeficiency virus type 1 virion binding, fusion, and infectivity but does not affect the CD4 binding site on gp120 or soluble CD4-induced conformational changes in gp120. J. Virol. 73:4360-4371.
146. Bewley CA (2001) Solution structure of a cyanovirin-N: Mana1-2Mana complex: Structural basis for high-affinity carbohydrate-mediated binding to gp120. Structure 9:931-940.
147. Tsai CC, Emau P, Jiang Y, Agy M, Shattock RJ, Schmidt A, Morton WR, Gustafson KR, Boyd MR (2004) Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res. Hum. Retroviruses 20:11-18.
148. Webster RG (2000) Immunity to influenza in the elderly. Vaccine 18:1686-1689.
149. Abdel-Motal UM, Guay HM, Wigglesworth K, Welsh RM, Galili U (2007) Immunogenicity of influenza virus vaccine is increased by anti-Gal-mediated targeting to antigen-presenting cells. J. Virol. 81:9131-9141.
150. Galili U, Rachmilewitz E, Peleg A, Flechner I (1984) A unique natural human IgG antibody with anti-alpha-galactosyl specificity. J. Exp. Med. 160:1519-1531.
151. Galili U (1993) Evolution and pathophysiology of the human natural anti-a-galactosyl IgG (anti-Gal) antibody. Springer Semin. Immunopathol. 15:155-171.
152. Henion TR, Gerhard W, Anaraki F, Galili U (1997) Synthesis of a-gal epitopes on influenza virus vaccines, by recombinant a1,3galactosyltransferase, enables the formation of immune complexes with the natural anti-Gal antibody. Vaccine 15:1174-1182.
153. Abdel-Motal U, Wang S, Lu S, Wigglesworth K, Galili U (2006) Increased immunogenicity of human immunodeficiency virus gp120 engineered to express Gal1-3Galß1-4GlcNAc-R epitopes. J. Virol. 80:6943-6951.
154. LaTemple D, Abrams J, Zhang S, Galili U (1999) Increased immunogenicity of tumor vaccines complexed with anti-Gal: Studies in knockout mice for alpha1,3galactosyltransferase. Cancer Res. 59:3417-3423